Standard preclinical approaches are poorly predictive, particularly for drugs eliciting human-specific toxicity or idiosynchratic DILI. In this webinar, Dr. Anthony Berger, a Field Application Scientist at CN Bio will discuss how liver-on-a-chip (LOAC) cocultures of primary hepatocytes offer a solution.

By more accurately recapitulating organ-level functionality, they provide a way to predict acute, chronic, and idiosyncratic human drug toxicity and understand the mechanism behind the cause. He will review how to date, ease-of use, throughput and cost limitations have restricted the widespread use of organ-on-a-chip (OOC) technologies, but next-generation solutions enable their human-relevant insights to be actionable earlier than ever before.

Key learning objectives

Discover how to:

• Address poorly met areas of preclinical toxicology using advanced human in vitro models
• Generate mechanistic signatures of toxicity to understand the cause
• Gain human-relevant insights early enough to recover flawed candidates
• Derive clinically relevant measurements to improve data translatability